EHA in the BioMed Alliance: joining forces for biomedical research

At a recent meeting at the European Parliament, Prof.

Recommendations for COVID-19

Publications

Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry
Aiello TF, Salmanton-Garcia J, Marchesi F, et al. Haematologica. 2024 Aug 1;109(8):2693-2700.

“Complement-ing” positive outcomes during the COVID-19 pandemic

Dr Dimitrios Mastellos (@dmastellos)

The COVID-19 pandemic has had a huge impact on research worldwide. Multiple projects have been halted and researchers have lost their jobs.

ASCERTAIN: EHA joins consortium aiming for better pricing and reimbursement models

November 28, 2022
EHA is a partner in the ASCERTAIN consortium which will develop models for the pricing, cost-benefit assessment, and reimbursement of innovative health technologies in Europe.

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

The European Union must deliver funding for research of blood disorders

At the 20th Annual Congress of EHA, the results of two major projects are presented. The first is a study into the Cost of Blood Disorders in the EU Member States and Norway, Iceland, and Switzerland.

The importance of education and collaboration for the treatment of patients

This article is written in the context of EHA’s membership of the European Alliance for Personalised Medicine (EAPM) where EHA takes a lead in the development of a strategy for education in personalized medicine. Read the full article here